Phenylbutyrate therapy for maple syrup urine disease

Nicola Brunetti-pierri, Brendan Lanpher, Ayelet Erez, Elitsa A. Ananieva, Mohammad Islam, Juan C. Marini, Qin Sun, Chunli Yu, Madhuri Hegde, Jun Li, R. Max Wynn, David T. Chuang, Susan Hutson, Brendan Lee

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Therapy with sodium phenylacetate/benzoate or sodium phenylbutyrate in urea cycle disorder patients has been associated with a selective reduction in branched-chain amino acids (BCAA) in spite of adequate dietary protein intake. Based on this clinical observation, we investigated the potential of phenylbutyrate treatment to lower BCAA and their corresponding α-keto acids (BCKA) in patients with classic and variant late-onset forms of maple syrup urine disease (MSUD). We also performed in vitro and in vivo experiments to elucidate the mechanism for this effect. We found that BCAA and BCKA are both significantly reduced following phenylbutyrate therapy in control subjects and in patients with late-onset, intermediate MSUD. In vitro treatment with phenylbutyrate of control fibroblasts and lymphoblasts resulted in an increase in the residual enzyme activity, while treatment of MSUD cells resulted in the variable response which did not simply predict the biochemical response in the patients. In vivo phenylbutyrate increases the proportion of active hepatic enzyme and unphosphorylated form over the inactive phosphorylated form of the E1α subunit of the branched-chain α-keto acid dehydrogenase complex (BCKDC). Using recombinant enzymes, we show that phenylbutyrate prevents phosphorylation of E1α by inhibition of the BCKDC kinase to activate BCKDC overall activity, providing a molecular explanation for the effect of phenylbutyrate in a subset of MSUD patients. Phenylbutyrate treatment may be a valuable treatment for reducing the plasma levels of neurotoxic BCAA and their corresponding BCKA in a subset of MSUD patients and studies of its long-term efficacy are indicated.

Original languageEnglish (US)
Article numberddq507
Pages (from-to)631-640
Number of pages10
JournalHuman Molecular Genetics
Volume20
Issue number4
DOIs
StatePublished - Feb 2011

Fingerprint

Phenylbutyrates
Maple Syrup Urine Disease
Branched Chain Amino Acids
3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide)
Keto Acids
Therapeutics
Enzymes
Inborn Urea Cycle Disorder
Sodium Benzoate
Dietary Proteins
Phosphotransferases
Fibroblasts
Phosphorylation
Observation
Liver

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Molecular Biology

Cite this

Brunetti-pierri, N., Lanpher, B., Erez, A., Ananieva, E. A., Islam, M., Marini, J. C., ... Lee, B. (2011). Phenylbutyrate therapy for maple syrup urine disease. Human Molecular Genetics, 20(4), 631-640. [ddq507]. https://doi.org/10.1093/hmg/ddq507

Phenylbutyrate therapy for maple syrup urine disease. / Brunetti-pierri, Nicola; Lanpher, Brendan; Erez, Ayelet; Ananieva, Elitsa A.; Islam, Mohammad; Marini, Juan C.; Sun, Qin; Yu, Chunli; Hegde, Madhuri; Li, Jun; Wynn, R. Max; Chuang, David T.; Hutson, Susan; Lee, Brendan.

In: Human Molecular Genetics, Vol. 20, No. 4, ddq507, 02.2011, p. 631-640.

Research output: Contribution to journalArticle

Brunetti-pierri, N, Lanpher, B, Erez, A, Ananieva, EA, Islam, M, Marini, JC, Sun, Q, Yu, C, Hegde, M, Li, J, Wynn, RM, Chuang, DT, Hutson, S & Lee, B 2011, 'Phenylbutyrate therapy for maple syrup urine disease', Human Molecular Genetics, vol. 20, no. 4, ddq507, pp. 631-640. https://doi.org/10.1093/hmg/ddq507
Brunetti-pierri N, Lanpher B, Erez A, Ananieva EA, Islam M, Marini JC et al. Phenylbutyrate therapy for maple syrup urine disease. Human Molecular Genetics. 2011 Feb;20(4):631-640. ddq507. https://doi.org/10.1093/hmg/ddq507
Brunetti-pierri, Nicola ; Lanpher, Brendan ; Erez, Ayelet ; Ananieva, Elitsa A. ; Islam, Mohammad ; Marini, Juan C. ; Sun, Qin ; Yu, Chunli ; Hegde, Madhuri ; Li, Jun ; Wynn, R. Max ; Chuang, David T. ; Hutson, Susan ; Lee, Brendan. / Phenylbutyrate therapy for maple syrup urine disease. In: Human Molecular Genetics. 2011 ; Vol. 20, No. 4. pp. 631-640.
@article{a70030fc187e42339c885f9fd09e07f4,
title = "Phenylbutyrate therapy for maple syrup urine disease",
abstract = "Therapy with sodium phenylacetate/benzoate or sodium phenylbutyrate in urea cycle disorder patients has been associated with a selective reduction in branched-chain amino acids (BCAA) in spite of adequate dietary protein intake. Based on this clinical observation, we investigated the potential of phenylbutyrate treatment to lower BCAA and their corresponding α-keto acids (BCKA) in patients with classic and variant late-onset forms of maple syrup urine disease (MSUD). We also performed in vitro and in vivo experiments to elucidate the mechanism for this effect. We found that BCAA and BCKA are both significantly reduced following phenylbutyrate therapy in control subjects and in patients with late-onset, intermediate MSUD. In vitro treatment with phenylbutyrate of control fibroblasts and lymphoblasts resulted in an increase in the residual enzyme activity, while treatment of MSUD cells resulted in the variable response which did not simply predict the biochemical response in the patients. In vivo phenylbutyrate increases the proportion of active hepatic enzyme and unphosphorylated form over the inactive phosphorylated form of the E1α subunit of the branched-chain α-keto acid dehydrogenase complex (BCKDC). Using recombinant enzymes, we show that phenylbutyrate prevents phosphorylation of E1α by inhibition of the BCKDC kinase to activate BCKDC overall activity, providing a molecular explanation for the effect of phenylbutyrate in a subset of MSUD patients. Phenylbutyrate treatment may be a valuable treatment for reducing the plasma levels of neurotoxic BCAA and their corresponding BCKA in a subset of MSUD patients and studies of its long-term efficacy are indicated.",
author = "Nicola Brunetti-pierri and Brendan Lanpher and Ayelet Erez and Ananieva, {Elitsa A.} and Mohammad Islam and Marini, {Juan C.} and Qin Sun and Chunli Yu and Madhuri Hegde and Jun Li and Wynn, {R. Max} and Chuang, {David T.} and Susan Hutson and Brendan Lee",
year = "2011",
month = "2",
doi = "10.1093/hmg/ddq507",
language = "English (US)",
volume = "20",
pages = "631--640",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Phenylbutyrate therapy for maple syrup urine disease

AU - Brunetti-pierri, Nicola

AU - Lanpher, Brendan

AU - Erez, Ayelet

AU - Ananieva, Elitsa A.

AU - Islam, Mohammad

AU - Marini, Juan C.

AU - Sun, Qin

AU - Yu, Chunli

AU - Hegde, Madhuri

AU - Li, Jun

AU - Wynn, R. Max

AU - Chuang, David T.

AU - Hutson, Susan

AU - Lee, Brendan

PY - 2011/2

Y1 - 2011/2

N2 - Therapy with sodium phenylacetate/benzoate or sodium phenylbutyrate in urea cycle disorder patients has been associated with a selective reduction in branched-chain amino acids (BCAA) in spite of adequate dietary protein intake. Based on this clinical observation, we investigated the potential of phenylbutyrate treatment to lower BCAA and their corresponding α-keto acids (BCKA) in patients with classic and variant late-onset forms of maple syrup urine disease (MSUD). We also performed in vitro and in vivo experiments to elucidate the mechanism for this effect. We found that BCAA and BCKA are both significantly reduced following phenylbutyrate therapy in control subjects and in patients with late-onset, intermediate MSUD. In vitro treatment with phenylbutyrate of control fibroblasts and lymphoblasts resulted in an increase in the residual enzyme activity, while treatment of MSUD cells resulted in the variable response which did not simply predict the biochemical response in the patients. In vivo phenylbutyrate increases the proportion of active hepatic enzyme and unphosphorylated form over the inactive phosphorylated form of the E1α subunit of the branched-chain α-keto acid dehydrogenase complex (BCKDC). Using recombinant enzymes, we show that phenylbutyrate prevents phosphorylation of E1α by inhibition of the BCKDC kinase to activate BCKDC overall activity, providing a molecular explanation for the effect of phenylbutyrate in a subset of MSUD patients. Phenylbutyrate treatment may be a valuable treatment for reducing the plasma levels of neurotoxic BCAA and their corresponding BCKA in a subset of MSUD patients and studies of its long-term efficacy are indicated.

AB - Therapy with sodium phenylacetate/benzoate or sodium phenylbutyrate in urea cycle disorder patients has been associated with a selective reduction in branched-chain amino acids (BCAA) in spite of adequate dietary protein intake. Based on this clinical observation, we investigated the potential of phenylbutyrate treatment to lower BCAA and their corresponding α-keto acids (BCKA) in patients with classic and variant late-onset forms of maple syrup urine disease (MSUD). We also performed in vitro and in vivo experiments to elucidate the mechanism for this effect. We found that BCAA and BCKA are both significantly reduced following phenylbutyrate therapy in control subjects and in patients with late-onset, intermediate MSUD. In vitro treatment with phenylbutyrate of control fibroblasts and lymphoblasts resulted in an increase in the residual enzyme activity, while treatment of MSUD cells resulted in the variable response which did not simply predict the biochemical response in the patients. In vivo phenylbutyrate increases the proportion of active hepatic enzyme and unphosphorylated form over the inactive phosphorylated form of the E1α subunit of the branched-chain α-keto acid dehydrogenase complex (BCKDC). Using recombinant enzymes, we show that phenylbutyrate prevents phosphorylation of E1α by inhibition of the BCKDC kinase to activate BCKDC overall activity, providing a molecular explanation for the effect of phenylbutyrate in a subset of MSUD patients. Phenylbutyrate treatment may be a valuable treatment for reducing the plasma levels of neurotoxic BCAA and their corresponding BCKA in a subset of MSUD patients and studies of its long-term efficacy are indicated.

UR - http://www.scopus.com/inward/record.url?scp=78751694242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78751694242&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddq507

DO - 10.1093/hmg/ddq507

M3 - Article

VL - 20

SP - 631

EP - 640

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 4

M1 - ddq507

ER -